Testing WVE-N531 for Duchenne muscular dystrophy exon 53
Part of Bones, joints & muscles, Brain & nervous system, Genetic & congenital clinical trials.
This early-phase study tests WVE-N531 in people with Duchenne muscular dystrophy (DMD) whose genetics specifically match an “exon 53” change. It may help by targeting the muscle disease process, and it includes procedures like muscle biopsies and regular heart/lung checks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your child) have a confirmed diagnosis of Duchenne muscular dystrophy (DMD).
- Your DMD genetic result shows a mutation that can be treated with an exon 53 approach.
- You are male, and you can be walking or not walking depending on which part of the study you enter.
- You can do study muscle biopsies, ideally from the deltoid (shoulder) muscle.
- Heart and lung tests are stable enough for participation (specific breathing and heart pumping thresholds).
- If you take steroid medicine for DMD, the dose must have stayed the same for several months before screening.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new gene therapy called SGT-003 for children with Duchenne muscular dystrophy. It aims to help the body produce a working version of dystrophin, the protein missing in Duchenne.
This study tests a one-time gene therapy given by injection into the spinal fluid (intrathecal) for boys with Duchenne muscular dystrophy. It aims to see if the treatment is safe and how it spreads in the body, and may offer a new way to slow the disease.
This trial tests a new gene therapy called SGT-003 in boys and men with Duchenne muscular dystrophy who are still able to walk. The treatment aims to deliver a working version of the dystrophin gene to help muscle cells produce the protein they are missing.
This trial is for people who have already taken WVE-N531 in an earlier study. It continues to check the medicine's safety and effects over a longer period.
This trial tests a new drug (NS-089/NCNP-02) that aims to help boys with Duchenne muscular dystrophy produce a shorter but still working version of the dystrophin protein. It's for boys who are still walking and have a specific genetic type that can be fixed by skipping a part of the gene called exon 44.
This study tests a new medication called KER-065 to see if it helps people with Duchenne Muscular Dystrophy (DMD). It may help boys and men who are still walking, as well as those who use a wheelchair, as long as they are on a stable corticosteroid treatment.
Hear when a new Duchenne Muscular Dystrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.